Industry Resources | August 28, 2012
SULT4A1-1 Guided Antipsychotic Therapy Can Greatly Reduce Schizophrenia Hospitalization Costs
August 28, 2012
The study was conducted by SureGene, LLC, which develops and markets tests to facilitate personalized prescribing based on the presence or absence of genetic biomarkers associated with medication response or adverse events. The report is based on an analysis of rehospitalization data from Caucasian patients participating in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study who consented to genotyping.
  . . .
Restricted Content
You must be an Elite member to view this resource.
